Bachem Holding AG: Company Profile
Background
Overview
Bachem Holding AG, founded in 1971 by Peter Grogg, is a Swiss biotechnology company specializing in the development and manufacture of peptides and oligonucleotides. With over 50 years of experience, Bachem provides products for research, clinical development, and commercial applications to pharmaceutical and biotechnology companies worldwide. The company operates internationally, with its headquarters in Bubendorf, Switzerland, and additional locations in Europe, the United States, and Asia. Bachem is listed on the SIX Swiss Exchange.
Mission and Vision
Bachem's mission is to be the world's leading specialist in peptides and oligonucleotides, aiming for unmatched market position, sales exceeding CHF one billion, and strong profitability to maintain independence. The company envisions being the most trusted and reliable partner for pharmaceutical and biotech companies, contributing significantly to the discovery and development of innovative medicines that help treat and cure various diseases. Bachem also strives to be a great place to work for team-minded individuals who want to make an impact.
Key Strategic Focus
Core Objectives
Bachem focuses on long-term partnerships, innovation, technological leadership, highest quality, and operational excellence. The company aims to attract, retain, and develop highly motivated, well-qualified individuals, fostering a unique corporate culture characterized by a spirit of partnership, openness, and team spirit. Bachem is committed to continuous improvement, increasing efficiency, and implementing more efficient business processes along the entire value chain.
Areas of Specialization
Bachem specializes in the development and manufacture of peptides and oligonucleotides, offering a comprehensive range of services, including custom and catalog peptide synthesis, development of nucleic acid-based therapeutics, and optimization of manufacturing processes for complex organic compounds.
Key Technologies Utilized
The company employs advanced technologies in peptide synthesis, oligonucleotide manufacturing, and process development. Bachem has invested in automated liquid-phase peptide synthesis and oligonucleotide capabilities, enhancing its manufacturing processes and product quality.
Primary Markets Targeted
Bachem serves pharmaceutical and biotechnology companies worldwide, focusing on therapeutic areas such as oncology, diabetes, and metabolic disorders. The company has expanded its presence in Asia, establishing a sales office in Tokyo, Japan, to strengthen customer support and drive business growth in the Asian market.
Financials and Funding
Funding History
Bachem went public on June 18, 1998, with shares listed on the Swiss Stock Exchange. In 2020, the company generated over CHF 400 million in sales for the first time and hired 272 new employees. Bachem plans to invest more than CHF 400 million in expansion over the next five years.
Recent Funding Rounds
Specific details about recent funding rounds are not publicly disclosed.
Notable Investors
As a publicly listed company, Bachem's shareholders include institutional and individual investors. The majority of shares are held by the company's founder, Peter Grogg.
Utilization of Capital
Bachem utilizes its capital for expanding manufacturing capacities, investing in research and development, and enhancing its global presence to meet the growing demand for peptides and oligonucleotides. The company has invested in new facilities in Bubendorf, Switzerland, and plans to expand its presence in the United States and Asia.
Pipeline Development
Key Pipeline Candidates
Bachem is involved in the development and production of peptides and oligonucleotides for various therapeutic areas, including oncology, diabetes, and metabolic disorders. The company has secured multi-year contracts representing approximately CHF 100 million in future revenue and operates a dedicated oligonucleotide facility at approximately 85% utilization.
Stages of Clinical Trials or Product Development
Specific details about the stages of clinical trials or product development for individual pipeline candidates are not publicly disclosed.
Target Conditions
Bachem focuses on therapeutic areas such as oncology, diabetes, and metabolic disorders.
Anticipated Milestones
The company has secured multi-year contracts and is expanding its manufacturing capacity to meet the growing demand for peptide and oligonucleotide-based therapeutics. Bachem's new facility in Bubendorf, Switzerland, is scheduled to become operational in 2024, significantly increasing production capacity.
Technological Platform and Innovation
Proprietary Technologies
Bachem has developed proprietary technologies in peptide synthesis and oligonucleotide manufacturing, including automated liquid-phase peptide synthesis and advanced oligonucleotide capabilities. The company has increased its patents in oligonucleotide manufacturing by approximately 15% year-on-year.
Significant Scientific Methods
Bachem employs advanced scientific methods in peptide synthesis, oligonucleotide manufacturing, and process development, focusing on continuous improvement and efficiency. The company has invested in automated liquid-phase peptide synthesis and oligonucleotide capabilities, enhancing its manufacturing processes and product quality.
AI-Driven Capabilities
Specific details about AI-driven capabilities are not publicly disclosed.
Leadership Team
Executive Profiles
- Thomas Meier: CEO of Bachem Holding AG, leading the company's strategic direction and operations.
- Kuno Sommer: Chairman of the Board of Directors, overseeing the company's governance and strategic initiatives.
- Anne-Kathrin Stoller: Chief Executive Officer, Senior Management, joined in 2026.
- Alain Schaffter: Chief Financial Officer, Senior Management, joined in 2020.
- Hans Van Hees: Chief Operating Officer, Senior Management, joined in 2025.
Key Contributions
The leadership team has been instrumental in Bachem's growth, overseeing strategic expansions, technological advancements, and the establishment of a strong global presence.
Competitor Profile
Market Insights and Dynamics
The global market for peptide and oligonucleotide-based therapeutics is experiencing significant growth, driven by advancements in biotechnology and increasing demand for targeted treatments. Bachem holds approximately 30% market share in the global peptide API manufacturing market, positioning it as a market leader ahead of competitors like PolyPeptide Group.
Competitor Analysis
- PolyPeptide Group: A direct competitor in the peptide API manufacturing space, offering similar services in peptide synthesis and manufacturing for pharmaceutical applications.
- Lonza Group: A Swiss contract development and manufacturing organization (CDMO) that offers peptide and oligonucleotide manufacturing services as part of its broader portfolio.
- Merck KGaA: Through its MilliporeSigma division, competes in the research peptides segment.
- Nitto Denko Avecia: Specialized in oligonucleotide manufacturing, competing with Bachem in the oligonucleotide therapeutics market.
Strategic Collaborations and Partnerships
In November 2025, Bachem entered into a partnership with TIRmed Pharma to develop and manufacture TIR-01, the active ingredient in next-generation atopic dermatitis therapy.
Operational Insights
Bachem's strategic focus on high-value oligonucleotides and capacity expansion positions it to meet the growing demand for peptide and oligonucleotide-based therapeutics. The company's investment in new facilities and technological advancements enhances its competitive advantage.
Strategic Opportunities and Future Directions
Bachem plans to invest more than CHF 400 million in expansion over the next five years, focusing on increasing manufacturing capacity and enhancing its global presence to meet the growing demand for peptides and oligonucleotides.
